VX-661 (F508del CFTR Corrector): Mechanism, Evidence, and Research Integration

Executive Summary: VX-661 (CAS 1152311-62-0) is a small-molecule corrector developed by Vertex Pharmaceuticals and supplied by APExBIO (SKU A2664) for research use in cystic fibrosis models. It targets the misfolded F508del CFTR protein, restoring its trafficking and surface expression in human bronchial epithelial cells [product]. VX-661 increases CFTR-mediated chloride channel activity up to 25% of wild-type levels when combined with potentiator VX-770 and a cAMP agonist [Tedman et al., 2025]. Its efficacy depends on experimental conditions, cell type, and the presence of molecular chaperones such as calnexin [Mechanistic Insights]. VX-661 has been benchmarked in vitro and in clinical dosing regimens, showing significant improvements in FEV1 and sweat chloride in F508del homozygous and heterozygous patients [Benchmarks]. Researchers must adhere to solubility, storage, and dosing parameters for reproducible results [Workflows].

Biological Rationale

Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CFTR gene. The F508del mutation is the most common, present in ~70% of CF alleles worldwide [CFF]. This mutation leads to misfolding and premature degradation of the CFTR protein in the endoplasmic reticulum (ER), preventing its localization to the apical plasma membrane [Tedman et al., 2025]. Loss of functional CFTR impairs chloride ion transport, causing thickened mucus, recurrent infections, and progressive lung disease. Small-molecule correctors such as VX-661 are designed to rescue defective CFTR folding and trafficking, restoring partial function [Small-Molecule CFTR Corrector].

Mechanism of Action of VX-661 (F508del CFTR corrector)

VX-661, also known by its IUPAC name 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide, acts as a type II CFTR corrector [APExBIO]. It binds to misfolded F508del CFTR within the ER, facilitating proper folding and assembly. VX-661 partially reverts the folding and processing defects, increasing CFTR levels at the plasma membrane. The compound enhances chloride channel activity in vitro, especially when combined with the potentiator VX-770 (ivacaftor), which increases channel gating. However, chronic co-administration with VX-770 can reduce VX-661 efficacy, necessitating optimized treatment protocols [Mechanistic Insights]. Calnexin, an endogenous ER chaperone, is critical for VX-661-mediated rescue, particularly for variants affecting the CFTR C-terminal domains [Tedman et al., 2025].

Evidence & Benchmarks

• VX-661 restores trafficking and surface expression of F508del CFTR in human bronchial epithelial cells at concentrations of 3 μM for 24 hours at 26°C (Tedman et al., 2025, https://doi.org/10.7554/eLife.107180).
• Combination of chronic VX-661 and acute VX-770 with a cAMP agonist increases chloride conductance to ~25% of wild type in CFBE41o- cells (Taylor-Cousar et al., 2017, https://pubmed.ncbi.nlm.nih.gov/28992432/).
• Clinical administration of oral VX-661 at 100-150 mg daily for 28 days improves FEV1 and reduces sweat chloride in F508del CFTR homozygous and heterozygous patients (Middleton et al., 2019, https://pubmed.ncbi.nlm.nih.gov/30767351/).
• VX-661 is soluble at ≥21.8 mg/mL in DMSO and ≥24.3 mg/mL in water, but insoluble in ethanol (APExBIO, https://www.apexbt.com/vx-661.html).
• Calnexin dependency is variant-specific: loss of calnexin disrupts VX-661 efficacy in CFTR variants with poor basal expression (Tedman et al., 2025, https://doi.org/10.7554/eLife.107180).

For an in-depth translational and mechanistic perspective, see the Mechanistic Insights and Translational Guide, which this article extends by focusing on practical integration and updated calnexin-dependent findings.

Applications, Limits & Misconceptions

VX-661 is primarily indicated for in vitro and in vivo research on F508del CFTR correction. The compound is highly effective in cell models (e.g., CFBE41o-) and has been validated in human clinical studies targeting F508del homozygous and heterozygous genotypes. Use in combination with VX-770 potentiator and cAMP agonists can maximize CFTR rescue. Researchers should note that VX-661 efficacy is modulated by cellular chaperones, with calnexin playing a crucial role for certain CFTR domains [Tedman et al., 2025]. Not all CFTR mutations respond equally to VX-661, and some rare variants are refractory to correction. The compound is for research use only and not intended for diagnostic or therapeutic purposes.

Common Pitfalls or Misconceptions

• VX-661 is not universally effective for all CFTR mutations; efficacy is highest for F508del and lower for other rare variants.
• Chronic co-administration with VX-770 may decrease the correction efficacy of VX-661; treatment protocols must be optimized for timing and dose [Mechanistic Insights].
• Solubility in ethanol is poor; DMSO or water are required for stock solution preparation [APExBIO].
• Storage of VX-661 solutions at temperatures above -20°C or for extended periods reduces compound stability.
• VX-661 is not approved for clinical therapy outside of approved combination regimens; use in patients must follow regulatory guidance.

For troubleshooting and workflow support, see Applied Workflows & Troubleshooting with VX-661, which this article clarifies by detailing calnexin-dependent boundaries and storage caveats.

Workflow Integration & Parameters

VX-661 is supplied as a solid by APExBIO (SKU A2664), and should be dissolved in DMSO (≥21.8 mg/mL) or water (≥24.3 mg/mL) [APExBIO product page]. Ethanol is unsuitable due to insolubility. Stock solutions may be stored below -20°C for several months, but repeated freeze-thaw cycles or long-term storage are discouraged. Typical cell-based assays use VX-661 at 3 μM, applied for 24 hours at 26°C in CFBE41o- human bronchial epithelial cells. For combination therapy studies, acute VX-770 and cAMP agonists are added post-corrector incubation. Clinical studies have used oral doses of 10–150 mg daily for 28 days, with 100 or 150 mg most effective in F508del homozygous/heterozygous patients. For reproducible results, researchers should standardize cell model, compound preparation, exposure time, and temperature. For scenario-driven optimization, see Lab-Proven Scenarios with VX-661, which this article updates by integrating solubility and workflow parameters.

Conclusion & Outlook

VX-661 (F508del CFTR corrector) is a mechanistically validated tool for restoring CFTR folding, trafficking, and chloride channel activity in cystic fibrosis models. Its efficacy is well-supported in both cellular and clinical contexts, with critical dependence on chaperone context and optimized workflows. APExBIO supplies VX-661 as a research reagent with validated solubility and storage parameters. Future research will refine genotype-specific and chaperone-dependent correction strategies. VX-661 remains indispensable for CFTR modulation studies, especially when paired with potentiators and cAMP agonists.